中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

80 records (took 0.053 seconds)

    DIFFERENTIAL EXPRESSION OF ORGANELLAR GENE PRODUCTS
    31.
    发明申请
    DIFFERENTIAL EXPRESSION OF ORGANELLAR GENE PRODUCTS 审中-公开
    有机基因产物的差异表达

    公开(公告)号：WO0055323A9

    公开(公告)日：2001-11-15

    申请号：PCT/US0007311

    申请日：2000-03-16

    Applicant: MITOKOR ,  HERRNSTADT CORRINA ,  MILLER SCOTT W ,  DAVIS ROBERT E

    Inventor： HERRNSTADT CORRINA ,  MILLER SCOTT W ,  DAVIS ROBERT E

    IPC: G01N33/50 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P25/28 ,  C07K14/47 ,  C12N15/09 ,  C12N15/10 ,  C12N15/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  C12N5/10 ,  G01N33/53

    CPC classification number: C12N15/1072 ,  C07K14/47 ,  C07K14/4711

    Abstract: Compositions and methods are provided for identifying factors, including organellar factors, that are differentially expressed when cells in different states, such as metabolic, respiratory, disease or apoptotic states, are compared. In preferred embodiments the invention relates to mitochondria DNA depleted ( rho ) and cytoplasmic hybrid (cybrid) cells, such as mitochondrial cybrid cells. Use of the invention to identify species specific expression of organellar factors such as organelle associated macromolecules is contemplated. Also disclosed are examples of organellar factors that are differentially expressed in organelle associated disease, including a variety of human genes that are differentially expressed in Alzheimer's disease.

    Abstract translation: 提供了组合物和方法，用于鉴别比较不同状态的细胞如代谢，呼吸，疾病或凋亡状态时差异表达的因子，包括细胞因子。 在优选的实施方案中，本发明涉及线粒体DNA耗尽（rhoO）和细胞质杂交（cybrid）杂交细胞，如线粒体细胞杂交细胞。 预期本发明用于鉴定细胞器因子如细胞器相关大分子的物种特异性表达的用途。 还公开了在细胞器相关疾病中差异表达的细胞因子的实例，包括在阿尔茨海默氏病中差异表达的各种人基因。

    PROCESS FOR INCREASING THE ACTIVITY OF ZEOLITE CONTAINING PARTICULATE SOLIDS
    32.
    发明申请
    PROCESS FOR INCREASING THE ACTIVITY OF ZEOLITE CONTAINING PARTICULATE SOLIDS 审中-公开
    增加含沸石颗粒物质活性的方法

    公开(公告)号：WO1997024182A1

    公开(公告)日：1997-07-10

    申请号：PCT/US1996020057

    申请日：1996-12-20

    Applicant: DAVIS, Robert, E. ,  BARTHOLIC, David, B.

    IPC: B01J29/90

    CPC classification number: B01J38/60 ,  B01J29/90 ,  B01J38/48 ,  B01J38/62

    Abstract: A process for increasing the activity of a zeolite-containing particulate solid containing contaminants which block the pores of the zeolite and adversely affect the activity thereof wherein the contaminated zeolitic material is slurried with a liquid containing an acid, detergent or surfactant, the slurry is agitated to liberate the pore-blocking contaminants from the zeolite pores so that they are suspended in the liquid, a portion of the liquid is withdrawn from the slurry and filtered to remove the suspended contaminants, the resulting liquid is returned to the slurry, and the treated zeolite-containing particulate solid is removed from the solution and recovered.

    Abstract translation: 一种提高含有沸石的颗粒固体的活性的方法，该固体含有阻碍沸石孔隙并且不利地影响其活性的污染物，其中污染的沸石材料用含有酸，洗涤剂或表面活性剂的液体浆化，搅拌浆液 为了释放孔隙阻塞污染物从沸石孔中，使得它们悬浮在液体中，一部分液体从浆料中排出并过滤以除去悬浮的污染物，将所得液体返回到浆料中，并将处理过的 从溶液中除去含沸石的颗粒状固体并回收。

    APPARATUS AND METHOD FOR REMOVAL OF IMPURITIES FROM LIQUEFIED PETROLEUM GAS
    35.
    发明申请
    APPARATUS AND METHOD FOR REMOVAL OF IMPURITIES FROM LIQUEFIED PETROLEUM GAS 审中-公开
    从液化石油气中清除污染物的装置和方法

    公开(公告)号：WO2003086568A1

    公开(公告)日：2003-10-23

    申请号：PCT/US2003/010170

    申请日：2003-04-03

    Applicant: FUEL TREATMENT TECHNOLOGIES, LLC ,  MEMMOTT, Bryan, S. ,  DAVIS, Robert, E.

    Inventor： MEMMOTT, Bryan, S. ,  DAVIS, Robert, E.

    IPC: B01D15/00

    CPC classification number: B01J20/12 ,  B01D15/00 ,  B01J20/0292 ,  B01J20/16 ,  B01J20/18 ,  B01J20/20 ,  B01J20/28078

    Abstract: A filter (2) and a method of using the filter for removing contaminants from LPG. The LPG enters the filter through an inlet (22) and passes through a first filtration element (42) where chemical contaminants are removed by a chemical entrapping agent, preferably a zeolite. Subsequently, the LPG passes through a second filtration element (48) where particulate contaminants are removed. The invention is also a method of removing contaminants from LPG including the step of routing the flow of the LPG through chemical and particulate filter elements so that chemical and particulate contaminants are sequentially removed.

    Abstract translation: 一种过滤器（2）和使用该过滤器去除来自LPG的污染物的方法。 LPG通过入口（22）进入过滤器，并通过第一过滤元件（42），其中通过化学截留剂（优选沸石）除去化学污染物。 随后，LPG通过其中除去微粒污染物的第二过滤元件（48）。 本发明也是从LPG中除去污染物的方法，包括通过化学和微粒过滤元件布置LPG流的步骤，从而顺序地除去化学和微粒污染物。

    COBALT-PORPHYRIN COMPLEXES AND USE THEREOF AS AN ANTI-OBESITY AGENT
    37.
    发明申请
    COBALT-PORPHYRIN COMPLEXES AND USE THEREOF AS AN ANTI-OBESITY AGENT 审中-公开
    钴 - 卟啉配合物及其作为抗肥胖剂的用途

    公开(公告)号：WO0248154A2

    公开(公告)日：2002-06-20

    申请号：PCT/US0148279

    申请日：2001-12-14

    Applicant: MITOKOR ,  SZABO TOMAS R ,  GHOSH SOUMITRA S ,  DAVIS ROBERT E

    Inventor： SZABO TOMAS R ,  GHOSH SOUMITRA S ,  DAVIS ROBERT E

    IPC: A61K31/409 ,  A61K33/24 ,  A61P3/04 ,  C07D487/22 ,  C07F15/06 ,  C07F

    CPC classification number: C07D487/22

    Abstract: Cobalt-porphyrin (Co-P) complexes for use as anti-obesity agents, and compositions and methods related thereto. The Co-P complexes exhibit reduced redox activity compared to cobalt mesoporphyrin (Co-MP) and cobalt protoporphyrin (Co-PP), which alleviates the deleterious effects associated with administration of Co-P associated with oxidative stress, particularly in the context of injection site toxicity.

    Abstract translation: 用作抗肥胖剂的钴 - 卟啉（Co-P）络合物，以及与其相关的组合物和方法。 与钴中卟啉（Co-MP）和钴原卟啉（Co-PP）相比，Co-P络合物表现出减少的氧化还原活性，其减轻了与施用与氧化应激有关的Co-P相关的有害作用，特别是在注射 现场毒性。

    DIAGNOSTIC ASSAY FOR DIABETES MELLITUS BASED ON MUTATIONAL BURDEN
    39.
    发明申请
    DIAGNOSTIC ASSAY FOR DIABETES MELLITUS BASED ON MUTATIONAL BURDEN 审中-公开
    基于MUTATIONAL BURDEN的糖尿病患者的诊断测定

    公开(公告)号：WO0066782A3

    公开(公告)日：2001-04-05

    申请号：PCT/US0011619

    申请日：2000-04-28

    Applicant: MITOKOR ,  DAVIS ROBERT E ,  HERRNSTADT CORINNA

    Inventor： DAVIS ROBERT E ,  HERRNSTADT CORINNA

    IPC: A61K38/00 ,  C07D219/08 ,  C07K14/47 ,  C12N9/02 ,  C12Q1/68 ,  C12N9/14 ,  C12N15/11

    CPC classification number: C07D219/08 ,  A61K38/00 ,  C07K14/4711 ,  C07K14/4713 ,  C12N9/0053 ,  C12Q1/6806 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2527/101

    Abstract: The present invention relates to genetic mutations in mitochondrial genes that segregate with diabetes mellitus. The invention provides methods for detecting such mutations, as a diagnostic for diabetes mellitus, either before or after the onset of clinical symptoms. Examples of specific mutations in the ATP synthase 8/6 sequence and tRNA sequence are given. The invention also provides treatments for dysfunctions due to genes for mitochondrial functions that segregate with diabetes mellitus. Cybrid cell lines are described which are useful as model systems for the study of the mitochondrial metabolic disorders that are associated with diabetes mellitus, and for identifying therapeutic compounds and treatments for this disease.

    Abstract translation: 本发明涉及与糖尿病分离的线粒体基因中的遗传突变。 本发明提供在临床症状发作之前或之后检测这种突变作为糖尿病诊断的方法。 给出了ATP合成酶8/6序列和tRNA 序列中特异性突变的实例。 本发明还提供了由于与糖尿病分离的线粒体功能的基因引起的功能障碍的治疗。 描述了杂交细胞系，其可用作研究与糖尿病相关的线粒体代谢紊乱的模型系统，并且用于鉴定该疾病的治疗化合物和治疗。

    DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS
    40.
    发明申请
    DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS 审中-公开
    诊断，治疗和细胞与动物模型的疾病相关的麻醉缺陷

    公开(公告)号：WO1995026973A1

    公开(公告)日：1995-10-12

    申请号：PCT/US1995004063

    申请日：1995-03-30

    Applicant: APPLIED GENETICS, INC. ,  HERRNSTADT, Corinna ,  PARKER, William, Davis ,  DAVIS, Robert, E. ,  MILLER, Scott, William

    Inventor： APPLIED GENETICS, INC.

    IPC: C07H21/04

    CPC classification number: C07K14/4713 ,  A61K38/00 ,  C07D219/08 ,  C07K14/4711 ,  C12N9/0053 ,  C12Q1/6806 ,  C12Q2527/101

    Abstract: The present invention relates to genetic mutations in mitochondrial cytochrome c oxidase genes that segregate with Alzheimer's disease (AD), diabetes mellitus, Parkinson's disease and other diseases of mitochondrial origin. The invention provides methods for detecting these mutations, either before of after the onset of clinical symptoms. The invention further provides treatment of cytochrome c oxidase dysfunction. Cybrid cell lines which have utility as model systems for the study of disorders that are associated with mitochondrial defects are also described. The cybrids are constructed by treating immortal cell lines with an agent that irreversibly disables mitochondrial electron transport, and then transfecting the cells with mitochondria isolated from diseased tissue samples. One such cybrid was constructed using neuroblastoma cells and mitochondria from a patient suffering from Alzheimer's Disease. Methods for using such cybrids for screening drugs and therapies for utility in treating such disorders are also provided. In addition, cybrid animals, methods of producing them, and methods of using them in drug and therapy screening are also provided.

    Abstract translation: 本发明涉及与阿尔茨海默氏病（AD），糖尿病，帕金森病和其他线粒体起源的疾病分离的线粒体细胞色素c氧化酶基因中的遗传突变。 本发明提供了在临床症状发作之前检测这些突变的方法。 本发明进一步提供细胞色素c氧化酶功能障碍的治疗。 还描述了作为用于研究与线粒体缺陷相关的病症的模型系统的实用的细胞系。 通过用不可逆地禁用线粒体电子传递的试剂处理永生细胞系，然后用从病变组织样品中分离的线粒体转染细胞来构建细胞。 使用神经母细胞瘤细胞和来自患有阿尔茨海默病的患者的线粒体构建一个这样的细胞周期。 还提供了使用这种细胞用于筛选药物的方法和用于治疗这种疾病的疗法。 此外，还提供了细胞杂种动物，其制备方法以及将其用于药物和治疗筛选中的方法。

Patent Agency Ranking